Symptom Burden In Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

被引：0
|
作者：
Williams, Loretta A.
Ault, Patricia S.
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Quintas-Cardama, Alfonso
Borthakur, Gautam
Faderl, Stefan H.
Jabbour, Elias J.
Cleeland, Charles S.
Cortes, Jorge E.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2988
引用
收藏
页数：1
相关论文
共 50 条
  • [21] WHO classification af acute myeloid leukaemia (AML) and the myelodysplastic syndrome (MDS)
    Haferlach, T
    Schoch, C
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (09) : 447 - 450
  • [22] Plasma DNA as a source of diagnostic and monitoring material in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Rogers, A
    Joe, Y
    Manshouri, T
    Giles, F
    Estey, EH
    Freireich, EJ
    Keating, MJ
    Kantarjian, HM
    Albitar, M
    BLOOD, 2001, 98 (11) : 576A - 576A
  • [23] IMMUNOHISTOCHEMICAL AND CYTOGENETIC CORRELATION WITH TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS)
    Chai, J.
    Nwaoduah, N.
    Shi, Y.
    Verma, A.
    Gong, J.
    Wang, Y.
    LEUKEMIA RESEARCH, 2021, 108 : S23 - S24
  • [24] Therapy-related myelodysplastic syndrome (t-MDS) following treatment of acute myeloid leukemia (AML)
    Arana-Yi, C.
    Block, A. W.
    Sait, S. N.
    Ford, L. A.
    Barcos, M.
    Baer, M. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Identification of Dido1 Mutation Associated with Familial Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML)
    Galili, Naomi
    Trifonov, Vladimir
    Ewalt, Mark
    Mukherjee, Siddhartha
    Rabadan, Raul
    Raza, Azra
    BLOOD, 2012, 120 (21)
  • [26] Del 5q as a sole cytogenetic abnormality in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Washington, LT
    Glassman, A
    Ibrahim, S
    Lai, R
    LABORATORY INVESTIGATION, 2001, 81 (01) : 182A - 182A
  • [27] Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) Associated with PARP Inhibitors: A Real-World Analysis
    Gajra, Ajeet
    Zettler, Marjorie E.
    Klink, Andrew J.
    Feinberg, Bruce
    BLOOD, 2020, 136
  • [28] Del 5q as a sole cytogenetic abnormality in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Washington, LT
    Glassman, A
    Ibrahim, S
    Lai, R
    MODERN PATHOLOGY, 2001, 14 (01) : 182A - 182A
  • [29] Rigosertib activity in patients with a myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) relapsed or refractory to hypomethylating agents
    Navada, S. C.
    Odchimar-Reissig, R.
    Reddy, E. P.
    Demakos, E. P.
    Holland, J. F.
    Wilhelm, F.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2013, 37 : S146 - S146
  • [30] Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment
    Alhajahjeh, Abdulrahman
    Stahl, Maximilian
    Kim, Tae K.
    Kewan, Tariq
    Stempel, Jessica M.
    Zeidan, Amer M.
    Bewersdorf, Jan Philipp
    EXPERT REVIEW OF ANTICANCER THERAPY, 2025,
12345